VIKING GLOBAL INVESTORS LP 13D and 13G filings for 4D Molecular Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:31 pm Sale | 2024-09-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT | VIKING GLOBAL INVESTORS LP | 0 0.000% | -4,247,914 (Position Closed) | Filing |
| 2024-01-08 4:15 pm Sale | 2024-01-04 | 13G | 4D Molecular Therapeutics, Inc. FDMT | VIKING GLOBAL INVESTORS LP | 4,247,914 9.900% | -540,000 (-11.28%) | Filing |
| 2024-01-08 4:05 pm Purchase | 2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | VIKING GLOBAL INVESTORS LP | 4,787,914 11.200% | 850,000 (+21.59%) | Filing |
| 2022-02-14 5:02 pm Unchanged | 2021-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | VIKING GLOBAL INVESTORS LP | 3,937,914 12.300% | 0 (Unchanged) | Filing |
| 2021-02-12 7:58 pm Unchanged | 2020-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | VIKING GLOBAL INVESTORS LP | 3,937,914 14.900% | 0 (Unchanged) | Filing |
| 2020-12-21 5:27 pm Purchase | 2020-12-15 | 13G | 4D Molecular Therapeutics, Inc. FDMT | VIKING GLOBAL INVESTORS LP | 3,937,914 14.900% | 3,937,914 (New Position) | Filing |